These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36613795)

  • 1. From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors.
    Hsieh CY; Sung SF
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review.
    Song J; Li X; Ni J
    Kidney Blood Press Res; 2023; 48(1):599-610. PubMed ID: 37717569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
    Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)-A Narrative Review.
    Iordan L; Gaita L; Timar R; Avram V; Sturza A; Timar B
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease.
    Clemmer JS; Yen TE; Obi Y
    Physiol Rep; 2023 Nov; 11(21):e15836. PubMed ID: 37957121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations.
    Beal B; Schutte AE; Neuen BL
    Curr Hypertens Rep; 2023 Dec; 25(12):429-435. PubMed ID: 37948021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of cardiovascular benefits of SGLT2 inhibitors.
    Zhang Y; Han Q
    Medicine (Baltimore); 2022 Sep; 101(36):e30310. PubMed ID: 36086785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes.
    Georgianos PI; Kourtidou C; Divani M; Liakopoulos V
    Expert Opin Pharmacother; 2024 Feb; 25(2):127-130. PubMed ID: 38407201
    [No Abstract]   [Full Text] [Related]  

  • 9. SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback.
    Upadhyay A
    Kidney360; 2024 May; 5(5):771-782. PubMed ID: 38523127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 Inhibitors in Kidney Diseases-A Narrative Review.
    Gajewska A; Wasiak J; Sapeda N; Młynarska E; Rysz J; Franczyk B
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comment on "The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease".
    Chen IW; Chang LC; Hung KC
    Int Urol Nephrol; 2024 Jun; 56(6):2115-2116. PubMed ID: 38252260
    [No Abstract]   [Full Text] [Related]  

  • 12. Investigational new drugs for the treatment of chronic renal failure: an overview of the literature.
    Terzo C; Gembillo G; Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Peritore L; Santoro D
    Expert Opin Investig Drugs; 2024 Apr; 33(4):319-334. PubMed ID: 38429874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists.
    Jaswaney R; Sokoloff S; Rakita V; Rubin DJ
    Cleve Clin J Med; 2024 Jul; 91(7):415-423. PubMed ID: 38950981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.
    Sridhar VS; Limonte CP; Groop PH; Heerspink HJL; Pratley RE; Rossing P; Skyler JS; Cherney DZI
    Diabetologia; 2024 Jan; 67(1):3-18. PubMed ID: 37801140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors: approved for adults and cats but not for children with CKD.
    Gross O; Haffner D; Schaefer F; Weber LT
    Nephrol Dial Transplant; 2024 May; 39(6):907-909. PubMed ID: 38308509
    [No Abstract]   [Full Text] [Related]  

  • 16. Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors.
    Mashayekhi M; Safa BI; Gonzalez MSC; Kim SF; Echouffo-Tcheugui JB
    Trends Endocrinol Metab; 2024 May; 35(5):425-438. PubMed ID: 38423898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of SGLT2 inhibitors on anemia and their possible clinical implications.
    Cases A; Cigarrán S; Luis Górriz J; Nuñez J
    Nefrologia (Engl Ed); 2024; 44(2):165-172. PubMed ID: 38604895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Protein Diets and Its Synergistic Role in the SGLT2 Inhibitor Era.
    Patel J; Kalantar-Zadeh K; Joshi S
    Adv Kidney Dis Health; 2023 Nov; 30(6):523-528. PubMed ID: 38453269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of hypoxia in chronic kidney disease: a nuanced perspective.
    Faivre A; de Seigneux S
    Curr Opin Nephrol Hypertens; 2024 Jul; 33(4):414-419. PubMed ID: 38597413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose cotransporter 2 inhibitors: are they ready for prime time in the management of lupus nephritis?
    Wagner BR; Rao PS
    Curr Opin Rheumatol; 2024 May; 36(3):163-168. PubMed ID: 38517337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.